Mechanisms of Therapeutic Resistance in Prostate Cancer.
- Published in:
- Current Oncology Reports, 2017, v. 19, n. 2, p. 1, doi. 10.1007/s11912-017-0568-7
- By:
- Publication type:
- Article
Works matching IS 15233790 AND DT 2017 AND VI 19 AND IP 2
Results: 7
1
2
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
- Published in:
- Current Oncology Reports, 2017, v. 19, n. 2, p. 1, doi. 10.1007/s11912-017-0566-9
- By:
- Publication type:
- Article
3
Radionuclide Therapy for Neuroendocrine Tumors.
- Published in:
- Current Oncology Reports, 2017, v. 19, n. 2, p. 1, doi. 10.1007/s11912-017-0567-8
- By:
- Publication type:
- Article
4
Current Management Strategy for Active Surveillance in Prostate Cancer.
- Published in:
- Current Oncology Reports, 2017, v. 19, n. 2, p. 1, doi. 10.1007/s11912-017-0569-6
- By:
- Publication type:
- Article
5
Multidimensional Treatment of Cancer Pain.
- Published in:
- Current Oncology Reports, 2017, v. 19, n. 2, p. 1, doi. 10.1007/s11912-017-0570-0
- By:
- Publication type:
- Article
6
The Potential Role of Symptom Questionnaires in Palliative and Supportive Cancer Care Delivery.
- Published in:
- Current Oncology Reports, 2017, v. 19, n. 2, p. 1, doi. 10.1007/s11912-017-0571-z
- By:
- Publication type:
- Article
7
Current Management of Refractory Germ Cell Tumors and Future Directions.
- Published in:
- Current Oncology Reports, 2017, v. 19, n. 2, p. 1, doi. 10.1007/s11912-017-0572-y
- By:
- Publication type:
- Article